1-5 of 5
Jeffrey A. Betcher, R.Ph
Close
Sort by
Journal Articles

Does Allogeneic Hematopoietic Cell Transplantation Benefit Older (≥ 60) AML/MDS Patients With Monosomal Karyotype?

James L Slack, MD, Nandita Khera, MD, MPH, Veena Fauble, MD, Jose F Leis, MD, PhD, Lisa Sproat, MD, MSW, Jared Klein, MD, Craig B. Reeder, MD, Jeffrey A Betcher, R.Ph., Pierre Noel, MD
Journal: Blood
Blood (2013) 122 (21): 3399.
https://doi.org/10.1182/blood.V122.21.3399.3399
Published: 2013
Journal Articles

Reduced Toxicity Conditioning With Fludarabine, BCNU, Melphalan and Anti-Thymocyte Globulin Followed By Allogeneic Stem Cell Transplant For Patients With Primary and Post ET/PV Myelofibrosis: Single Center Experience At Mayo Clinic Arizona

Veena Fauble, MD, Ruben A. Mesa, MD, Pierre Noel, MD, Roberta Adams, MD, Yu-hui Chang, PhD, Jose F Leis, MD, PhD, Nandita Khera, MD, MPH, Lisa Sproat, MD, MSW, Craig Reeder, MD, Jared Klein, MD, Jeffrey A Betcher, R.Ph., Meagan Higgins, NP, Lori DeCook, PA-C, Jane Palmer, NP, Susan Gerber, PA-C, Kimberly Henderson, PA-C, Kristen Beebe, PA-C, Rochelle Chiffelle, DNP, Jane Olsen, NP, Angela Toro, NP, James L Slack, MD
Journal: Blood
Blood (2013) 122 (21): 2835.
https://doi.org/10.1182/blood.V122.21.2835.2835
Published: 2013
Journal Articles

In-Vivo T-Cell Depletion with Rabbit Anti-Thymocyte Globulin (r-ATG) Prevents Severe Acute and Chronic Graft Versus Host Disease (GVHD) and Allows Safe Allogeneic Stem Cell Transplantation (allo-SCT) From Mismatched, Unrelated Donors

James L. Slack, MD, Jose F. Leis, MD, PhD, Craig B. Reeder, MD, Joseph R. Mikhael, MD, Pierre Noel, MD, Ruben A. Mesa, MD, Raoul Tibes, MD, PhD, Jeffrey A. Betcher, R.Ph, Mary E Peterson, C.N.P, Meagan S. Higgins, C.N.P, Ginger Gillette-Kent, C.N.P, Lisa D. Tremblay, N.P, Jane J. Olson, NP, Roberta H. Adams, MD
Journal: Blood
Blood (2011) 118 (21): 1977.
https://doi.org/10.1182/blood.V118.21.1977.1977
Published: 2011
Journal Articles

Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML): Low Incidence of Relapse and Graft Versus Host Disease (GVHD) in Patients (pts) Transplanted without Active Leukemia Using in-Vivo T-Cell Depletion with Rabbit Anti-Thymocyte Globulin (r-ATG)

James L. Slack, MD, Jose F. Leis, MD, PhD, Craig B. Reeder, MD, Joseph R. Mikhael, MD, Raoul Tibes, MD, PhD, Pierre Noel, MD, Ruben A. Mesa, MD, Jeffrey A. Betcher, R.Ph, Mary E Peterson, C.N.P, Meagan S. Higgins, C.N.P, Ginger Gillette-Kent, C.N.P, Lisa D. Tremblay, N.P, Jane J Olsen, N.P, Roberta H. Adams, MD
Journal: Blood
Blood (2011) 118 (21): 4527.
https://doi.org/10.1182/blood.V118.21.4527.4527
Published: 2011
Journal Articles

Induction Therapy Followed by Allogeneic Stem Cell Transplant for MPN Blast Phase: Outcomes From Mayo Clinic in Arizona

Chad Cherington, MD, James L. Slack, MD, Jose F. Leis, MD, PhD, Roberta H. Adams, MD, Craig B. Reeder, MD, Joseph R. Mikhael, MD, John Camoriano, MD, Pierre Noel, MD, Raoul Tibes, MD, PhD, Jeffrey A. Betcher, R.Ph, Mary E Peterson, C.N.P, Meagan S. Higgins, C.N.P, Ginger Gillette-Kent, C.N.P, Lisa D. Tremblay, N.P, Jane J Olsen, N.P, Ruben A. Mesa, MD
Journal: Blood
Blood (2011) 118 (21): 1749.
https://doi.org/10.1182/blood.V118.21.1749.1749
Published: 2011